Precision BioSciences (DTIL) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

DTIL Stock Forecast

Precision BioSciences stock forecast is as follows: an average price target of $15.50 (represents a 238.43% upside from DTIL’s last price of $4.58) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

DTIL Price Target

The average price target for Precision BioSciences (DTIL) is $15.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $1.00. This represents a potential 238.43% upside from DTIL's last price of $4.58.

DTIL Analyst Ratings

Buy

According to 3 Wall Street analysts, Precision BioSciences's rating consensus is 'Buy'. The analyst rating breakdown for DTIL stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Precision BioSciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 01, 2024	Justin Zelin	BTIG	$30.00	$13.56	121.24%	555.02%
Nov 10, 2022		Goldman Sachs	$1.00	$1.38	-27.54%	-78.17%

The latest Precision BioSciences stock forecast, released on Apr 01, 2024 by Justin Zelin from BTIG, set a price target of $30.00, which represents a 121.24% increase from the stock price at the time of the forecast ($13.56), and a 555.02% increase from DTIL last price ($4.58).

Precision BioSciences Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$30.00
Last Closing Price	$4.58	$4.58	$4.58
Upside/Downside	-100.00%	-100.00%	555.02%

In the current month, the average price target of Precision BioSciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Precision BioSciences's last price of $4.58. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 04, 2024	BMO Capital	Market Perform	Market Perform	Hold
May 16, 2024	Guggenheim	Underperform	Underperform	Hold
May 16, 2024	H.C. Wainwright	Buy	Buy	Hold
Apr 01, 2024	BTIG	Buy	Buy	Hold
Jun 17, 2022	BMO Capital		Outperform	Initialise

Precision BioSciences's last stock rating was published by BMO Capital on Nov 04, 2024. The company gave DTIL a "Market Perform" rating, the same as its previous rate.

Precision BioSciences Financial Forecast

Precision BioSciences Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Revenue	-	-	-	-	-	-	-	-	-	$13.12M	$19.79M	$8.78M	$10.60M	$7.36M	$3.82M	$3.32M	$6.34M	$24.04M	$68.81M	$16.35M	$8.85M	$7.36M	$1.08M	$7.00M	$6.52M	$4.87M	$5.39M	$5.46M
Avg Forecast	$11.00M	$11.00M	$13.70M	$10.00M	$3.42M	$5.33M	$7.70M	$5.34M	$12.47M	$8.99M	$6.38M	$5.67M	$6.81M	$9.86M	$4.97M	$7.73M	$9.04M	$6.02M	$13.86M	$8.30M	$5.93M	$4.34M	$5.09M	$4.14M	$8.74M	$6.21M	$8.00M	$5.55M
High Forecast	$13.37M	$13.37M	$16.65M	$12.15M	$4.16M	$5.36M	$7.70M	$5.34M	$15.15M	$9.19M	$7.75M	$6.90M	$8.27M	$9.86M	$4.97M	$7.73M	$9.04M	$6.02M	$13.86M	$8.30M	$5.93M	$4.34M	$5.09M	$4.14M	$8.74M	$6.21M	$8.00M	$5.55M
Low Forecast	$9.33M	$9.33M	$11.63M	$8.49M	$2.90M	$5.31M	$7.70M	$5.34M	$10.58M	$8.79M	$5.41M	$4.82M	$5.78M	$9.86M	$4.97M	$7.73M	$9.04M	$6.02M	$13.86M	$8.30M	$5.93M	$4.34M	$5.09M	$4.14M	$8.74M	$6.21M	$8.00M	$5.55M
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	1.46%	3.10%	1.55%	1.56%	0.75%	0.77%	0.43%	0.70%	3.99%	4.96%	1.97%	1.49%	1.69%	0.21%	1.69%	0.75%	0.78%	0.67%	0.98%

Precision BioSciences's average Quarter revenue forecast for Dec 23 based on 2 analysts is $12.47M, with a low forecast of $10.58M, and a high forecast of $15.15M. DTIL's average Quarter revenue forecast represents a -4.96% decrease compared to the company's last Quarter revenue of $13.12M (Sep 23).

Precision BioSciences EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	$-11.53M	$-11.89M	$-23.76M	$-16.01M	$-21.29M	$-28.63M	$-25.87M	$-19.74M	$-8.65M	$24.34M	$-16.22M	$-20.98M	$-23.52M	$-30.25M	$-24.45M	$-19.11M	$-19.34M	$-18.27M	$-30.66M
Avg Forecast	$-8.43M	$-8.43M	$-10.50M	$-7.67M	$-2.62M	$-4.09M	$-5.90M	$-4.09M	$-9.56M	$-6.89M	$-4.89M	$-4.35M	$-5.22M	$-7.84M	$-3.96M	$-29.70M	$-7.19M	$-4.79M	$-11.02M	$-21.74M	$-4.72M	$-3.46M	$-4.05M	$-24.45M	$-6.95M	$-4.94M	$-6.37M	$-85.62M
High Forecast	$-7.16M	$-7.16M	$-8.91M	$-6.51M	$-2.22M	$-4.07M	$-5.90M	$-4.09M	$-8.11M	$-6.74M	$-4.15M	$-3.69M	$-4.43M	$-7.84M	$-3.96M	$-23.76M	$-7.19M	$-4.79M	$-11.02M	$-17.39M	$-4.72M	$-3.46M	$-4.05M	$-19.56M	$-6.95M	$-4.94M	$-6.37M	$-68.49M
Low Forecast	$-10.25M	$-10.25M	$-12.76M	$-9.32M	$-3.19M	$-4.11M	$-5.90M	$-4.09M	$-11.62M	$-7.05M	$-5.94M	$-5.29M	$-6.34M	$-7.84M	$-3.96M	$-35.64M	$-7.19M	$-4.79M	$-11.02M	$-26.09M	$-4.72M	$-3.46M	$-4.05M	$-29.34M	$-6.95M	$-4.94M	$-6.37M	$-102.74M
Surprise %	-	-	-	-	-	-	-	-	-	1.67%	2.43%	5.46%	3.07%	2.72%	7.24%	0.87%	2.75%	1.81%	-2.21%	0.75%	4.45%	6.80%	7.47%	1.00%	2.75%	3.92%	2.87%	0.36%

1 analysts predict DTIL's average Quarter EBITDA for Sep 21 to be $-4.79M, with a high of $-4.79M and a low of $-4.79M. This is -119.67% lower than Precision BioSciences's previous annual EBITDA (Jun 21) of $24.34M.

Precision BioSciences Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	$-8.08M	$-11.89M	$-23.56M	$-36.49M	$-24.96M	$-32.47M	$-28.99M	$-22.34M	$-11.28M	$21.66M	$-18.69M	$-23.45M	$-26.02M	$-32.70M	$-26.84M	$-20.92M	$-20.74M	$-19.44M	$-31.78M
Avg Forecast	$-1.89M	$-2.40M	$-510.10K	$-2.77M	$-16.60M	$-15.57M	$-15.46M	$-17.26M	$-14.92M	$-39.90M	$-53.34M	$-49.41M	$-44.27M	$-70.12M	$-91.71M	$-32.34M	$-99.58M	$-124.51M	$-93.51M	$-25.04M	$-105.47M	$-138.30M	$-124.41M	$-26.84M	$-103.37M	$-105.88M	$-80.98M	$-88.75M
High Forecast	$-1.52M	$-1.93M	$-409.71K	$-2.22M	$-13.33M	$-12.50M	$-12.42M	$-13.87M	$-11.98M	$-32.05M	$-42.84M	$-39.68M	$-35.56M	$-70.12M	$-91.71M	$-25.87M	$-99.58M	$-124.51M	$-93.51M	$-20.03M	$-105.47M	$-138.30M	$-124.41M	$-21.47M	$-103.37M	$-105.88M	$-80.98M	$-71.00M
Low Forecast	$-2.42M	$-3.08M	$-652.84K	$-3.54M	$-21.25M	$-19.92M	$-19.79M	$-22.09M	$-19.10M	$-51.06M	$-68.27M	$-63.23M	$-56.66M	$-70.12M	$-91.71M	$-38.81M	$-99.58M	$-124.51M	$-93.51M	$-30.05M	$-105.47M	$-138.30M	$-124.41M	$-32.20M	$-103.37M	$-105.88M	$-80.98M	$-106.50M
Surprise %	-	-	-	-	-	-	-	-	-	0.20%	0.22%	0.48%	0.82%	0.36%	0.35%	0.90%	0.22%	0.09%	-0.23%	0.75%	0.22%	0.19%	0.26%	1.00%	0.20%	0.20%	0.24%	0.36%

Precision BioSciences's average Quarter net income forecast for Sep 21 is $-124.51M, with a range of $-124.51M to $-124.51M. DTIL's average Quarter net income forecast represents a -674.96% decrease compared to the company's last Quarter net income of $21.66M (Jun 21).

Precision BioSciences SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	$9.63M	$9.83M	$11.09M	$10.07M	$10.33M	$10.48M	$10.69M	$10.62M	$9.64M	$9.94M	$9.50M	$9.20M	$8.53M	$8.70M	$9.62M	$8.48M	$7.05M	$6.50M	$5.00M
Avg Forecast	$12.10M	$12.10M	$15.07M	$11.00M	$3.76M	$5.87M	$8.47M	$5.87M	$13.72M	$9.89M	$7.01M	$6.24M	$7.49M	$10.67M	$5.38M	$8.37M	$9.79M	$6.52M	$15.00M	$8.99M	$6.42M	$4.70M	$5.51M	$4.49M	$9.46M	$6.72M	$8.66M	$6.01M
High Forecast	$14.70M	$14.70M	$18.31M	$13.37M	$4.57M	$5.90M	$8.47M	$5.87M	$16.67M	$10.11M	$8.52M	$7.59M	$9.10M	$10.67M	$5.38M	$8.37M	$9.79M	$6.52M	$15.00M	$8.99M	$6.42M	$4.70M	$5.51M	$4.49M	$9.46M	$6.72M	$8.66M	$6.01M
Low Forecast	$10.27M	$10.27M	$12.79M	$9.33M	$3.19M	$5.84M	$8.47M	$5.87M	$11.64M	$9.67M	$5.95M	$5.30M	$6.35M	$10.67M	$5.38M	$8.37M	$9.79M	$6.52M	$15.00M	$8.99M	$6.42M	$4.70M	$5.51M	$4.49M	$9.46M	$6.72M	$8.66M	$6.01M
Surprise %	-	-	-	-	-	-	-	-	-	0.97%	1.40%	1.78%	1.35%	0.97%	1.95%	1.28%	1.09%	1.48%	0.66%	1.06%	1.43%	1.81%	1.58%	2.14%	0.90%	1.05%	0.75%	0.83%

Precision BioSciences's average Quarter SG&A projection for Dec 23 is $13.72M, based on 2 Wall Street analysts, with a range of $11.64M to $16.67M. The forecast indicates a 42.38% rise compared to DTIL last annual SG&A of $9.63M (Sep 23).

Precision BioSciences EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	$-0.07	$-0.00	$-0.21	$-0.33	$-0.23	$-0.48	$-0.47	$-0.37	$-0.19	$0.38	$-0.33	$-0.45	$-0.50	$-0.63	$-0.52	$-0.41	$-0.41	$-0.39	$-1.99
Avg Forecast	$-0.26	$-0.33	$-0.07	$-0.38	$-2.28	$-2.14	$-2.12	$-2.37	$-2.05	$-5.47	$-7.32	$-6.78	$-6.08	$-10.00	$-13.08	$-16.23	$-14.20	$-17.76	$-13.34	$-14.90	$-15.04	$-19.73	$-17.74	$-15.53	$-14.74	$-15.10	$-11.55	$-11.72
High Forecast	$-0.21	$-0.27	$-0.06	$-0.31	$-1.83	$-1.72	$-1.70	$-1.90	$-1.64	$-4.40	$-5.88	$-5.45	$-4.88	$-10.00	$-13.08	$-16.23	$-14.20	$-17.76	$-13.34	$-14.90	$-15.04	$-19.73	$-17.74	$-15.53	$-14.74	$-15.10	$-11.55	$-11.72
Low Forecast	$-0.33	$-0.42	$-0.09	$-0.49	$-2.92	$-2.73	$-2.72	$-3.03	$-2.62	$-7.01	$-9.37	$-8.68	$-7.77	$-10.00	$-13.08	$-16.23	$-14.20	$-17.76	$-13.34	$-14.90	$-15.04	$-19.73	$-17.74	$-15.53	$-14.74	$-15.10	$-11.55	$-11.72
Surprise %	-	-	-	-	-	-	-	-	-	0.01%	0.00%	0.03%	0.05%	0.02%	0.04%	0.03%	0.03%	0.01%	-0.03%	0.02%	0.03%	0.03%	0.04%	0.03%	0.03%	0.03%	0.03%	0.17%

According to 1 Wall Street analysts, Precision BioSciences's projected average Quarter EPS for Sep 21 is $-17.76, with a low estimate of $-17.76 and a high estimate of $-17.76. This represents a -4773.16% decrease compared to DTIL previous annual EPS of $0.38 (Jun 21).

Precision BioSciences Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PASG	Passage Bio	$0.67	$6.00	795.52%	Buy
BDTX	Black Diamond Therapeutics	$2.50	$20.00	700.00%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
DTIL	Precision BioSciences	$4.58	$15.50	238.43%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
PLRX	Pliant Therapeutics	$14.37	$35.50	147.04%	Buy
MREO	Mereo BioPharma Group	$3.40	$8.00	135.29%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
ALEC	Alector	$1.89	$4.00	111.64%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
CYTK	Cytokinetics	$47.78	$90.00	88.36%	Buy
DYN	Dyne Therapeutics	$26.16	$49.00	87.31%	Buy
RVMD	Revolution Medicines	$45.16	$65.67	45.42%	Buy
HOOK	HOOKIPA Pharma	$2.13	$3.00	40.85%	Buy

DTIL Forecast FAQ

Is Precision BioSciences a good buy?

Yes, according to 3 Wall Street analysts, Precision BioSciences (DTIL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of DTIL's total ratings.

What is DTIL's price target?

Precision BioSciences (DTIL) average price target is $15.5 with a range of $1 to $30, implying a 238.43% from its last price of $4.58. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Precision BioSciences stock go up soon?

According to Wall Street analysts' prediction for DTIL stock, the company can go up by 238.43% (from the last price of $4.58 to the average price target of $15.5), up by 555.02% based on the highest stock price target, and down by -78.17% based on the lowest stock price target.

Can Precision BioSciences stock reach $7?

DTIL's average twelve months analyst stock price target of $15.5 supports the claim that Precision BioSciences can reach $7 in the near future.

What are Precision BioSciences's analysts' financial forecasts?

Precision BioSciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $21.79M (high $22.55M, low $21.24M), average EBITDA is $-16.705M (high $-16.286M, low $-17.291M), average net income is $-64.89M (high $-52.119M, low $-83.047M), average SG&A $23.97M (high $24.81M, low $23.37M), and average EPS is $-8.905 (high $-7.152, low $-11.396). DTIL's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $45.7M (high $55.54M, low $38.78M), average EBITDA is $-35.034M (high $-29.73M, low $-42.575M), average net income is $-7.579M (high $-6.087M, low $-9.699M), average SG&A $50.27M (high $61.09M, low $42.66M), and average EPS is $-1.04 (high $-0.835, low $-1.331).

Did the DTIL's actual financial results beat the analysts' financial forecasts?

Based on Precision BioSciences's last annual report (Dec 2023), the company's revenue was $48.73M, beating the average analysts forecast of $33.51M by 45.40%. Apple's EBITDA was $-42.527M, beating the average prediction of $-25.691M by 65.53%. The company's net income was $-61.319M, missing the average estimation of $-158M by -61.08%. Apple's SG&A was $39.09M, beating the average forecast of $36.86M by 6.03%. Lastly, the company's EPS was $-0.016, missing the average prediction of $-21.622 by -99.93%. In terms of the last quarterly report (Sep 2023), Precision BioSciences's revenue was $13.12M, beating the average analysts' forecast of $8.99M by 45.88%. The company's EBITDA was $-11.532M, beating the average prediction of $-6.895M by 67.26%. Precision BioSciences's net income was $-8.079M, missing the average estimation of $-39.897M by -79.75%. The company's SG&A was $9.63M, missing the average forecast of $9.89M by -2.63%. Lastly, the company's EPS was $-0.0701, missing the average prediction of $-5.475 by -98.72%